Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Growth Hormone Treatment in Children with Perthes Disease and Growth Hormone Deficiency: A Case Report and Literature Review

Author(s): Yuzhen Shi, Yanqin Ying, Xiaoping Luo and Ling Hou*

Volume 23, Issue 13, 2023

Published on: 15 June, 2023

Page: [1668 - 1673] Pages: 6

DOI: 10.2174/1871530323666230504113023

Price: $65

Abstract

Background: Perthes disease is an idiopathic femoral head necrosis disease in children. Although it is believed that the prognosis after surgery within 5 years of age is good, there are very few reports in the literature regarding concurrent growth hormone deficiency and the outcome of growth hormone treatment. We retrospectively analyzed and summarized the clinical data of patients with Perthes disease and GHD in a child treated with rhGH for four years.

Case Presentation: We reported the case of an 11.9-year-old boy diagnosed with “Perthes disease” at 2.7 years. He underwent surgery at the age of 4.8 years and recovered well. At 6.7 years old, he was admitted for “slow growth in height for more than four years.” Physical examination demonstrated severe short stature with a height of 108.8 cm (< 3rd percentile, -2.45 standard deviation (SD)). The major abnormalities observed in the auxiliary examinations included low insulin-like growth factor-1 (IGF-1) (-1.73SD) and low GH peak levels (< 5 μg/L) in the growth hormone stimulation test. A diagnosis of complete GHD was confirmed, and low-dose rhGH treatment was administered. After four years of rhGH treatment, his height reached 152.3 cm (50th-75th percentile, + 0.29 SD). The annual growth rate was approximately 9.1 cm per year, and the curative effect was significant. No adverse reactions were observed during the treatment.

Conclusion: The benefits of rhGH in children with Perthes disease and GHD may outweigh its risks. However, its safety requires long-term follow-up evaluation.

« Previous Next »
Graphical Abstract

[1]
Ibrahim T, Little DG. The pathogenesis and treatment of Legg-Calvé-Perthes disease. JBJS Rev 2016; 4(7): e4.
[http://dx.doi.org/10.2106/JBJS.RVW.15.00063] [PMID: 27509329]
[2]
Mills S, Burroughs KE. Legg Calve Perthes Disease. Treasure Island, FL: StatPearls Publishing 2023.
[3]
Li H, Ji C, Zong X. Standardized growth curves of height and weight for children and adolescents aged 0-18 years in China. Zhonghua Er Ke Za Zhi 2009; 47(7): 487-92.
[PMID: 19951507]
[4]
Lindblad M, Josefsson A, Bladh M, Sydsjö G, Johansson T. Risk factors during pregnancy and delivery for the development of Perthes’ disease, a nationwide Swedish study of 2.1 million individuals. BMC Pregnancy Childbirth 2020; 20(1): 192.
[http://dx.doi.org/10.1186/s12884-020-2849-7] [PMID: 32228493]
[5]
Wiig O, Terjesen T, Svenningsen S, Lie SA. The epidemiology and aetiology of Perthes’ disease in Norway. J Bone Joint Surg Br 2006; 88-B(9): 1217-23.
[http://dx.doi.org/10.1302/0301-620X.88B9.17400] [PMID: 16943476]
[6]
Froberg L, Christensen F, Pedersen NW, Overgaard S. Long-term follow-up of a patient cohort with Legg–Calvé–Perthes disease. J Pediatr Orthop B 2011; 20(5): 273-7.
[http://dx.doi.org/10.1097/BPB.0b013e3283474268] [PMID: 21829143]
[7]
Laine JC, Martin BD, Novotny SA, Kelly DM. Role of advanced imaging in the diagnosis and management of active Legg-Calvé-Perthes disease. J Am Acad Orthop Surg 2018; 26(15): 526-36.
[http://dx.doi.org/10.5435/JAAOS-D-16-00856] [PMID: 29939867]
[8]
Leroux J, Abu Amara S, Lechevallier J. Legg-Calvé-Perthes disease. Orthop Traumatol Surg Res 2018; 104(1): S107-12.
[http://dx.doi.org/10.1016/j.otsr.2017.04.012] [PMID: 29155310]
[9]
Pavone V, Chisari E, Vescio A, Lizzio C, Sessa G, Testa G. Aetiology of Legg-Calvé-Perthes disease: A systematic review. World J Orthop 2019; 10(3): 145-65.
[http://dx.doi.org/10.5312/wjo.v10.i3.145] [PMID: 30918798]
[10]
Kim HKW. Legg-Calve-Perthes disease. J Pediatr Orthop 2011; 31(2) (Suppl.): S141-6.
[http://dx.doi.org/10.1097/BPO.0b013e318223b4bd] [PMID: 21857428]
[11]
Dixit M, Poudel SB, Yakar S. Effects of GH/IGF axis on bone and cartilage. Mol Cell Endocrinol 2021; 519: 111052.
[http://dx.doi.org/10.1016/j.mce.2020.111052] [PMID: 33068640]
[12]
Baş VN, Uytun S, Vurdem ÜE, Torun YA. Hypopituitarism and Legg-Calve-Perthes disease related to difficult delivery. Korean J Pediatr 2015; 58(7): 270-3.
[http://dx.doi.org/10.3345/kjp.2015.58.7.270] [PMID: 26300943]
[13]
Nishi Y, Tanaka T, Fujieda K, et al. Slipped capital femoral epiphysis, Perthes’ disease and scoliosis in children with growth hormone deficiency. Endocr J 1998; 45: S167-9.
[http://dx.doi.org/10.1507/endocrj.45.Suppl_S167] [PMID: 9790256]
[14]
Lamback EB, Chiarini S, Roposch A, Dattani MT. Congenital growth hormone deficiency associated with hip dysplasia and Legg‐Calve‐Perthes disease. Clin Endocrinol 2021; 94(4): 590-7.
[http://dx.doi.org/10.1111/cen.14365] [PMID: 33147364]
[15]
Clayton PE, Cowell CT. Safety issues in children and adolescents during growth hormone therapy—a review. Growth Horm IGF Res 2000; 10(6): 306-17.
[http://dx.doi.org/10.1054/ghir.2000.0175]
[16]
Fornari ED, Karkenny A, Schulz J. Legg-Calvé-Perthes disease. Curr Orthop Pract 2015; 26(5): 487-93.
[http://dx.doi.org/10.1097/BCO.0000000000000282]
[17]
Berthaume MA, Perry DC, Dobson CA, Witzel U, Clarke NM, Fagan MJ. Skeletal immaturity, rostral sparing, and disparate hip morphologies as biomechanical causes for Legg-Calvé-Perthes’ disease. Clin Anat 2016; 29(6): 759-72.
[http://dx.doi.org/10.1002/ca.22690] [PMID: 26780125]
[18]
Chen G, Chen T, Zhang P, et al. Can large doses of glucocorticoids lead to Perthes? A case report and review of the literature. BMC Pediatr 2021; 21(1): 339.
[http://dx.doi.org/10.1186/s12887-021-02755-4] [PMID: 34384372]
[19]
Hailer YD, Haag AC, Nilsson O. Legg-Calvé-Perthes disease. J Pediatr Orthop 2014; 34(5): 514-21.
[http://dx.doi.org/10.1097/BPO.0000000000000157] [PMID: 24787306]
[20]
Perry DC, Thomson C, Pope D, Bruce CE, Platt MJ. A case control study to determine the association between Perthes’ disease and the recalled use of tobacco during pregnancy, and biological markers of current tobacco smoke exposure. Bone Joint J 2017; 99-B(8): 1102-8.
[http://dx.doi.org/10.1302/0301-620X.99B8.BJJ-2016-1282.R1] [PMID: 28768789]
[21]
Ranke MB, Wit JM. Growth hormone - past, present and future. Nat Rev Endocrinol 2018; 14(5): 285-300.
[http://dx.doi.org/10.1038/nrendo.2018.22] [PMID: 29546874]
[22]
Haidar RK, Nasrallah MP, Der-Boghossian AH, Ghanem IB. Orthopedic complications related to growth hormone therapy in a pedi-atric population. J Pediatr Orthop B 2011; 20(1): 57-61.
[http://dx.doi.org/10.1097/BPB.0b013e32833ed967] [PMID: 20811297]
[23]
Lim WY, Germain-Lee EL, Dunbar NS. Legg-Calve-Perthes disease in an 8-year old girl with Acrodysostosis type 1 on growth hor-mone therapy: Case report. Int J Pediatr Endocrinol 2020; 2020(1): 15.
[http://dx.doi.org/10.1186/s13633-020-00085-3] [PMID: 32782451]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy